Clinical Trials Logo

Clinical Trial Summary

Open label, dose escalation to evaluate safety.


Clinical Trial Description

Evaluate safety, tolerability, and efficacy of various doses of STP705 administered as intralesional injection in subjects with facial isSCC. There will be 3 cohorts of 10 subjects each. Enrolled subjects will receive STP705 once weekly for 6 weeks. The lesion will be excised 60 days after. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05421013
Study type Interventional
Source Sirnaomics
Contact
Status Completed
Phase Phase 1/Phase 2
Start date August 1, 2022
Completion date March 29, 2023